A Phase Ib Study of Ibrutinib in Combination With Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase of Trial: Phase I
Latest Information Update: 16 Jul 2017
At a glance
- Drugs Obinutuzumab (Primary) ; Ibrutinib
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- 29 Jun 2016 Planned number of patients changed from 60 to 40.
- 14 Dec 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
- 04 Sep 2015 New trial record